Deplatt

Quick links to important sections

Deplatt

Selected form

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Deplatt

Property Description
Active ingredient Clopidogrel Bisulfate
Form Oral, Film-coated tablet
Pharmacological class Antiplatelet Agent (P2Y12 Inhibitor)
General purpose Maintenance of unobstructed blood flow
Origin Synthetic (Thienopyridine derivative)

What is Deplatt and its Pharmacological Class?

Deplatt is a commonly utilized brand name for the prescription-only medication containing the active compound Clopidogrel. The substance is chemically defined as a Thienopyridine derivative, a synthetic molecule with long-established clinical recognition in cardiovascular management. Clopidogrel is formally classified as an Antiplatelet Agent, or a platelet aggregation inhibitor, which means its action is specifically focused on modulating the function of blood platelets. This classification defines its role in reducing the potential for spontaneous clot formation within the blood vessels.

The Active Ingredient: Clopidogrel and its Physical Form

The core compound in this preparation is Clopidogrel Bisulfate, which is the precise chemical salt form of the active ingredient, formulated as a single product. Deplatt is consistently presented as an oral, film-coated tablet, a dosage form chosen to facilitate stable delivery of the active ingredient systemically. As a synthetic drug, its manufacture ensures high consistency and purity. This type of formulation is utilized to provide the necessary bioavailability for its long-term maintenance therapy function.

General Purpose: Reducing Platelet Activity

The overall purpose of this antiplatelet medication is to maintain unobstructed and continuous blood flow throughout the circulatory system. By inhibiting the natural 'stickiness' of platelets, the medicine prevents them from prematurely or inappropriately clumping together to form pathological internal clots, known as thrombi. This key function establishes its role as a fundamental maintenance therapy, typically used to continuously support vessel patency and smooth blood circulation.

What side effects are possible with Deplatt?

Official Regulatory Safety Profile

This safety information is based on authoritative government regulatory documents, outlining the established adverse reactions and critical warnings associated with Deplatt (Clopidogrel).

Key Risks and Serious Adverse Reactions

The most significant and defining risk is Bleeding, which can range from minor, commonly reported events to serious, life-threatening internal hemorrhage (such as intracranial or gastrointestinal bleeding). The risk of major bleeding is documented to be highest during the first month of treatment.

Serious, but rare, adverse reactions documented in regulatory sources include:

  • Thrombotic Thrombocytopenic Purpura (TTP): A rare, severe blood disorder requiring urgent intervention.
  • Severe Blood Cell Disorders: Including agranulocytosis, severe neutropenia, and aplastic anaemia/pancytopenia.
  • Severe Hypersensitivity Reactions: Such as Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and acute liver failure.

Adverse Reactions by Frequency

Official regulatory sources classify adverse reactions based on frequency:

Classification Examples of Documented Reactions
Common Haemorrhage (bruise, nosebleeds, GI bleed), Diarrhoea, Abdominal pain, Dyspepsia, Headache.
Uncommon Thrombocytopenia, Intracranial hemorrhage, Gastric/Duodenal ulcer, Urticaria.
Rare Severe neutropenia, Retroperitoneal haemorrhage.
Very Rare TTP, Agranulocytosis, Acute liver failure, SJS, TEN.

Safety Restrictions and Considerations

  • Contraindications: The medicine is not to be used in patients with active pathological bleeding (e.g., peptic ulcer) or severe hepatic impairment.
  • Genetic Warning: Regulatory labels highlight that some individuals (known as CYP2C19 poor metabolizers) may exhibit a diminished response to the medicine and remain at a higher risk for cardiovascular events.
  • Surgical Precaution: Temporary discontinuation 5 to 7 days before planned surgery is often necessary due to the risk of increased bleeding.

This information strictly details the drug’s safety framework as defined by government health authorities.

Overdose and Emergency Response

The official regulatory description of Clopidogrel (Deplatt) overdose is defined by the drug's effect on blood clotting. Overdose may lead to bleeding complications, including prolonged bleeding time and instances of unusual bruising or excessive bleeding. Regulatory documents categorize this risk as potentially severe and life-threatening, with possibilities such as gastrointestinal hemorrhage documented.

This serious risk establishes the mandatory course of action. In any instance of suspected overdose, individuals must seek immediate medical attention. Urgent contact with emergency services is required if severe clinical signs manifest, such as collapse, seizure, difficulty breathing, or an inability to be awakened.

The drug’s antiplatelet action is noted to be irreversible for the lifespan of the affected platelets, influencing the management strategy. No specific antidote is known to chemically reverse this effect. Therefore, management is symptomatic and supportive. Official prescribing information indicates that platelet transfusion is a procedural measure that may be used to restore clotting ability, particularly if severe bleeding is observed, which necessitates hospital monitoring and continuous observation.

Therapeutic Uses of Deplatt

What Deplatt Treats: Main Uses and Benefits

Deplatt (clopidogrel) is applied as a part of symptomatic management across domains where additional symptomatic support is needed, and plays a role in managing the risk of vascular events. The medicine is commonly used to help manage conditions characterized by periods of heightened symptoms such as Acute Coronary Syndrome (ACS), and in contexts involving patients who have experienced a recent myocardial infarction (MI) or stroke, as well as peripheral arterial disease (PAD).


Key Therapeutic Contexts

This medicine is applied in clinical settings that involve acute or unstable symptom patterns. It assists with addressing symptoms related to systemic imbalance and organ-specific functional stress. It is considered relevant because it provides supportive relief when symptoms interfere with routine activities and may contribute to improved day-to-day comfort.

Quick Fact: Supports Management of Systemic Imbalance


Condition Categories

Clopidogrel is relevant in conditions characterized by periods of heightened symptoms. It is commonly used to help manage contexts involving recent MI, recent stroke, and established PAD. It is also applied when appropriate to support patients following interventional procedures, such as coronary stent placement, to help cope more steadily with symptom fluctuations associated with the procedure.

Eligibility and Restrictions for Use

Deplatt (clopidogrel) is an antiplatelet medication used to prevent blood clots in adults. Regulatory documents define its eligibility based on specific clinical, physiological, and genetic statuses.

Populations Who Must NOT Use Deplatt

Contraindicated: Use is strictly prohibited for patients with:

  • Active Pathological Bleeding (e.g., bleeding peptic ulcer or intracranial hemorrhage).
  • Severe Hepatic Impairment (severe liver disease).
  • Hypersensitivity or Allergy to clopidogrel or any component of the product.

Populations Requiring Special Consideration

Population/Condition Eligibility Status Special Consideration (Official Terminology)
Pediatric Patients (Under 18) Use Not Established Safety and efficacy have not been established; use is not recommended.
Renal Impairment Restricted Use Use with caution; therapeutic experience is limited.
Moderate Hepatic Disease Restricted Use Use with caution due to limited experience and potential for bleeding diatheses.
Recent Ischemic Stroke Not Recommended Cannot be recommended during the first seven days following an acute ischemic stroke.
Poor CYP2C19 Metabolizers Diminished Efficacy May have reduced antiplatelet effect; alternative treatment should be considered.
Pregnancy/Lactation Not Recommended Use during pregnancy is not recommended as a precautionary measure. A decision must be made to discontinue nursing or discontinue the drug while breastfeeding.

Eligibility for Deplatt is primarily determined by ruling out high-risk bleeding states and severe liver dysfunction, which are formal contraindications. Restrictions exist for populations with compromised organ function, recent clinical events like stroke, and specific genetic factors that may reduce drug effectiveness or increase risk.

What should I know about interactions with other medicines?

Deplatt (clopidogrel) is a prodrug that requires activation by the enzyme CYP2C19 in the liver. Concomitant use with other medications that inhibit this enzyme can reduce the active metabolite's level, thereby decreasing Deplatt’s antiplatelet effect and potentially increasing the risk of adverse cardiovascular events.


Medications that Increase Bleeding Risk

The concurrent use of Deplatt with other agents that affect blood clotting or can cause gastrointestinal lesions significantly increases the risk of bleeding.

Drug Class Examples of Interacting Medicines
Anticoagulants Warfarin, Heparin
Other Antiplatelet Agents Aspirin (acetylsalicylic acid), Ticlopidine
NSAIDs Ibuprofen, Naproxen (Non-Steroidal Anti-Inflammatory Drugs)
Thrombolytics Medicines used to dissolve blood clots

Co-administration with these medicines should be approached with caution and requires close medical supervision.


CYP2C19 Inhibitors that Reduce Effectiveness

Certain Proton Pump Inhibitors (PPIs), used to reduce stomach acid, are strong CYP2C19 inhibitors. The use of omeprazole and esomeprazole with Deplatt is generally discouraged due to the risk of reduced antiplatelet action. Other PPIs, like pantoprazole or lansoprazole, may be preferred, though the potential for interaction should still be considered.

Other medicines that inhibit CYP2C19 and may interact include certain antidepressants (e.g., fluvoxamine, fluoxetine), some antifungal and antiviral agents (e.g., fluconazole, voriconazole), and other medicines (e.g., cimetidine, ticlopidine).

Mechanism of Action

How Deplatt Works: Core Mechanistic Domains

Prodrug Activation and Enzyme-Dependent Mechanism

The drug is an inactive prodrug that requires two-step chemical transformation by the Cytochrome P450 2C19 (CYP2C19) enzyme in the liver to yield the pharmacologically active molecule. This bioactivation is essential for the molecule to engage its target and is relevant to the initiation of specific signaling patterns.

Irreversible P2Y12 Receptor Inhibition

Following activation, the active metabolite selectively and irreversibly binds to the P2Y12 receptor on the surface of blood platelets, forming a covalent chemical bond. This mechanism permanently suppresses the receptor's function for the cell's lifespan, engaging specific receptor-mediated responses that lead to the sustained physiological adjustment of blood flow dynamics.

Inhibition of the Platelet Aggregation Cascade

Blockade of P2Y12 interrupts the signaling cascade initiated by the natural ligand ADP by preventing the activation of the Glycoprotein GPIIb/IIIa complex. This action modulates key pathways associated with platelet activation, resulting in impaired platelet cross-linking, which supports continuous blood flow.

Dosage and Administration Information

Deplatt (clopidogrel) is an oral tablet administered to adults based on a clear, standardized dosing schedule.

Official Administration Guidelines

Administration Scope Instruction
Route of Administration Oral
Standard Daily Dose One 75 mg tablet once a day for adults and the elderly.
Loading Dose For certain acute conditions, treatment is initiated with a single 300 mg oral loading dose to establish a rapid effect. For medically managed patients over 75 years of age in ST-segment elevation myocardial infarction (STEMI), the loading dose is typically omitted.
Timing and Food Intake The tablet must be taken regularly at the same time each day and may be taken with or without food.
Preparation Requirements None; the tablet is swallowed whole.

Missed Dose Instructions

If you forget a dose, the procedure is as follows to ensure correct use without double dosing:

  • If less than 12 hours have passed since the usual time, the forgotten dose should be taken immediately, and the next dose should be taken at the regularly scheduled time.
  • If more than 12 hours have passed, the missed dose should be skipped entirely. Only the next dose should be taken at its regular time; do not take a double dose to make up for the missed one.

Treatment Discontinuation

Treatment with this medicine must not be stopped unless specifically instructed by a doctor. Patients are advised to inform all healthcare professionals and dentists that they are taking clopidogrel prior to any scheduled surgery or procedure where the antiplatelet effect is temporarily not desirable.

Recent Clinical Evidence

Research evidence / Overview of studies for Deplatt

Evidence for use in Reducing Cardiovascular Events

Research has focused on the use of Deplatt (containing clopidogrel) in people who have experienced a heart attack, stroke, or have other established issues with blood flow in the arteries. This area was studied primarily through large, organized randomized controlled trials (RCTs). These studies monitored specific outcomes related to systemic or functional imbalance, such as the number of recurrent heart attacks and subsequent strokes. The research describes patterns observed in these large study populations, but findings describe group patterns, not individual predictions.

Evidence for use Following Coronary Procedures (Stenting)

Research has also explored the compound’s application in people who have recently undergone a procedure to place a stent. These studies often involved combining Deplatt with a second antiplatelet agent. Researchers examined outcomes linked to inflammatory states, focusing on clot formation inside the stent. What remains uncertain includes results when the compound is used alone in all patient types, and follow-up durations were limited in some original research, providing limited insight into long-term outcomes past the study’s endpoint.

Evidence for use in Peripheral Arterial Disease (PAD)

Research has examined the compound's application in people with Peripheral Arterial Disease (PAD), a condition marked by functional limitations. Studies monitored patient-reported outcomes describing perceived discomfort. However, the amount of dedicated research focusing solely on PAD is smaller than for other vascular conditions. Findings were mixed in some areas, meaning data are still emerging and certain long-term outcomes are not fully established for this specific condition.

Long-term Studies and What is Still Uncertain

Comparative studies were primarily designed to look at short-term or intermediate outcomes, often less than one year. Research exploring the duration of use over many years is more observational in nature, meaning certainty remains low regarding the full range of long-term outcomes. Data for certain specific groups, such as those with severe liver or kidney problems, remain insufficient. Ultimately, research does not determine whether an individual will respond similarly to the group patterns observed in studies.

Key Studies & References

  1. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease

Frequently Asked Questions (FAQ)

Common questions about Deplatt (FAQ)


Q: Are there any specific vitamins or supplements that interact with Deplatt?

Regulatory documents state that users should be sure their healthcare professional is aware of all supplements and herbal products they are taking. This is because some herbal supplements, such as garlic, ginger, and ginkgo, may increase the risk of bleeding when taken alongside this medicine.


Q: Does Deplatt cause headaches or dizziness in some users?

Yes, regulatory documents list headache as a common side effect of this medication. Dizziness has also been reported as a side effect, although it is generally classified as uncommon or less frequent in official sources.


Q: Is Deplatt used to treat high cholesterol?

No, this medicine is an antiplatelet agent used to prevent blood clots in people with cardiovascular disease. It is not indicated or used for the direct treatment of high cholesterol, although it is often prescribed together with cholesterol-lowering medicines.


Q: Can Deplatt increase the risk of bleeding in the eyes or nose?

The medicine is associated with an increased risk of bleeding. Official product information notes that general bleeding has been reported, which may include specific issues like nosebleeds (epistaxis) and, less commonly, bleeding in the eyes or other areas.


Q: What lifestyle changes, like diet and exercise, are recommended while taking Deplatt?

Official patient sources suggest general lifestyle habits like regular exercise and a balanced diet support overall heart health while on this medication. Official information indicates alcohol should be moderated, as it may increase the risk of stomach irritation or bleeding.


Q: Can taking Deplatt make me feel more tired or fatigued?

Official product information sometimes reports excessive tiredness (asthenia) as a possible side effect of the active ingredient. However, this is generally not listed among the most common adverse reactions experienced by users.


Q: Are there any documented cases of Deplatt causing allergic skin reactions?

Yes, allergic reactions are documented in the safety profile. Common reactions include rash and itching. More severe, though rare, reactions like generalized rash or conditions such as Stevens-Johnson Syndrome (SJS) have also been reported in official sources.


Q: Does grapefruit juice affect how Deplatt works in the body?

Scientific literature suggests that grapefruit juice may interfere with the enzymes needed to activate this medicine in the liver. This interference could potentially reduce the drug's effectiveness. Because of this potential interference, patients are generally advised to discuss grapefruit products with a healthcare professional.


Q: Can Deplatt interact with antidepressant medications like SSRIs?

Yes, regulatory data indicates an interaction risk. Certain antidepressants, particularly Selective Serotonin Reuptake Inhibitors (SSRIs) like fluoxetine, may inhibit the enzyme needed to activate the medicine, potentially reducing its effectiveness. The concurrent use of both medications also carries an increased overall risk of bleeding.


Q: What are the less common, but possible, gastrointestinal side effects besides basic stomach upset?

While basic stomach upset is common, official safety information notes that less common but possible gastrointestinal side effects include the development of a gastric or duodenal ulcer. Rare but serious bleeding in the gastrointestinal tract has also been reported.


Q: Is it normal to have heavier menstrual periods while taking Deplatt?

Due to the risk of general bleeding, some patient sources note that this effect may lead to heavier menstrual periods, though changes to menstruation are not always listed among the common side effects in all official product information.


Q: Is Deplatt meant to replace cholesterol-lowering medication?

No. This medicine is an antiplatelet agent and works by preventing blood clots. It has a different function than cholesterol-lowering medicines (statins). They are often prescribed together because they target different aspects of cardiovascular disease.


Q: Is Deplatt considered a scheduled drug or controlled substance?

No, official classifications confirm that this medicine is a prescription-only drug but is not classified as a federally controlled substance in the U.S. or under similar international scheduling systems.


Q: Does Deplatt interact with any common diabetes medications?

Yes, regulatory data suggests this medicine can interact with certain diabetes medications. For instance, it may increase the blood levels of drugs like repaglinide. Monitoring by a healthcare professional may be necessary.


Q: What is the difference between Deplatt and aspirin?

Both are antiplatelet agents used to prevent blood clots, but they work through different mechanisms. Deplatt is a P2Y12 inhibitor that blocks a specific receptor on platelets. Aspirin inhibits a different enzyme. They are often used together due to their distinct actions.


Q: Why is Deplatt sometimes prescribed along with aspirin (dual therapy)?

Studies, particularly those involving patients who have received a coronary stent, show that combining this medicine with a second antiplatelet agent like aspirin can be beneficial. This dual antiplatelet therapy (DAPT) provides a more intensive way to prevent serious clot formation.


Q: How long does it take for Deplatt to start working?

Official administration guidelines note that for acute conditions, a higher loading dose is often given to establish a rapid effect. For ongoing, long-term use, the full antiplatelet effect builds up over time after starting the daily maintenance dose.


Q: Is Deplatt safe for people with a history of liver problems?

Official information states that this medication is strictly prohibited in patients with severe liver impairment. For those with moderate liver disease, its use is restricted and requires caution due to limited experience and the potential for increased bleeding risk.


Q: Are there any special considerations for people with kidney disease taking Deplatt?

Yes, use in patients with kidney impairment is restricted and should be approached with caution by a healthcare professional. This is because therapeutic experience in this population is limited, and long-term data for people with severe kidney problems are not fully established.


Q: Can older adults take Deplatt without increased risks?

The standard daily dose is the same for adults and the elderly. However, in certain acute settings, a loading dose is typically omitted for medically managed patients over 75 years of age. Overall use in the elderly requires professional management and caution.


Q: What kind of research evidence supports the long-term use of Deplatt?

The initial research that established the medicine’s effectiveness relied on large, randomized controlled trials (RCTs). However, studies exploring the duration of use over many years are more observational in nature, meaning data on the full range of long-term outcomes is less certain than short-term results.


Q: What are the potential risks of taking Deplatt during pregnancy or while breastfeeding?

Use during pregnancy is generally not recommended as a precautionary measure. If breastfeeding, the official guidance requires a professional assessment to determine whether to discontinue nursing or discontinue the drug, based on the specific situation.


Q: Does alcohol consumption interfere with the effectiveness or safety of Deplatt?

While moderate alcohol is not strictly prohibited, excessive consumption may increase the risk of bleeding, especially in the stomach. Official information indicates that caution is necessary with alcohol intake while on this medication.


Q: Can Deplatt cause stomach issues like indigestion or pain?

Yes, official safety information lists abdominal pain, diarrhea, and indigestion (dyspepsia) as common side effects. The medicine is generally not used in people with active stomach ulcers.

How should Deplatt be stored and disposed of?

How to Store and Dispose of Deplatt?

This medication must be stored strictly according to its official labeled requirements to maintain stability and effectiveness.

Storage and Handling

Requirement Official Statement
Temperature Store at room temperature, generally below 30, C, and sometimes specified not above 25, C.
Protection Keep in the original container, tightly closed, away from excess heat and moisture.
Child Safety Keep out of the sight and reach of children and pets at all times.
In-Use Stability If supplied in an HDPE bottle, use within 6 months of first opening (where applicable).

Disposal Instructions

Do not dispose of this medication by flushing it down a toilet. Prioritize participation in local drug take-back programs or community disposal events for unused medicine. If take-back programs are unavailable, dispose of tablets in household trash by mixing them with an undesirable substance, such as dirt or cat litter, before sealing the mixture in a bag and discarding it.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Deplatt found in:

A-Z Index: